Neurocrine Q1 revenue rises to $572.6 million; GAAP EPS falls to $0.08
Neurocrine Biosciences reported first-quarter 2025 total revenues of $572.6 million, up from $515.3 million a year earlier, while GAAP diluted earnings per share fell to $0.08 from $0.42. The company reaffirmed its full-year 2025 INGREZZA net sales guidance of $2.5 billion to $2.6 billion, but higher R&D spending and a $30.6 million unrealized loss on equity investments reduced profit.
Key points
- INGREZZA first-quarter net product sales were $545.2 million, compared with $506.0 million a year earlier; CRENESSITY sales were $14.5 million.
- GAAP net income was $7.9 million, versus $43.4 million in Q1 2024; non-GAAP net income was $71.5 million, versus $124.8 million.
- Q1 2025 R&D expense includes $45 million of development milestones, mainly tied to starting the osavampator Phase 3 program in major depressive disorder.
- Cash, cash equivalents and marketable securities totaled $1,758.8 million at March 31, 2025, and $150 million of a $500 million buyback had been repurchased by that date.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.